| Literature DB >> 27973405 |
Stefan J Friedrichsdorf1,2, James Giordano3, Kavita Desai Dakoji4, Andrew Warmuth5, Cyndee Daughtry6, Craig A Schulz7,8.
Abstract
Primary pain disorders (formerly "functional pain syndromes") are common, under-diagnosed and under-treated in children and teenagers. This manuscript reviews key aspects which support understanding the development of pediatric chronic pain, points to the current pediatric chronic pain terminology, addresses effective treatment strategies, and discusses the evidence-based use of pharmacology. Common symptoms of an underlying pain vulnerability present in the three most common chronic pain disorders in pediatrics: primary headaches, centrally mediated abdominal pain syndromes, and/or chronic/recurrent musculoskeletal and joint pain. A significant number of children with repeated acute nociceptive pain episodes develop chronic pain in addition to or as a result of their underlying medical condition "chronic-on-acute pain." We provide description of the structure and process of our interdisciplinary, rehabilitative pain clinic in Minneapolis, Minnesota, USA with accompanying data in the treatment of chronic pain symptoms that persist beyond the expected time of healing. An interdisciplinary approach combining (1) rehabilitation; (2) integrative medicine/active mind-body techniques; (3) psychology; and (4) normalizing daily school attendance, sports, social life and sleep will be presented. As a result of restored function, pain improves and commonly resolves. Opioids are not indicated for primary pain disorders, and other medications, with few exceptions, are usually not first-line therapy.Entities:
Keywords: adolescents; biopsychosocial; children; chronic pain; interdisciplinary treatment; pediatric pain clinic; primary pain disorder
Year: 2016 PMID: 27973405 PMCID: PMC5184817 DOI: 10.3390/children3040042
Source DB: PubMed Journal: Children (Basel) ISSN: 2227-9067
Headache warning signals requiring further workup, including neuroimaging.
Focal or abnormal neurological signs, ataxia Papilledema (including rule out pseudotumor cerebri) Age < 3 years “Worst headache of my life” Progressive worsening headaches Ventriculoperitoneal-shunt Neurocutaneous syndrome Immunocompromised → Cerebrospinal fluid? (check with Infectious disease, oncology or transplant clinician) |
Rule out: carbon monoxide toxicity; Obstructive sleep apnea.
Abdominal pain warning signals requiring further workup.
Persistent right upper or right lower quadrant pain Pain that wakes child from sleep Dysphagia Arthritis Persistent vomiting Perirectal disease Gastrointestinal blood loss Involuntary weight loss Nocturnal diarrhea Deceleration of linear growth Unexplained fever |
Musculoskeletal/joint pain warning signals requiring further workup.
Arthralgia: Rubor, calor, edema Pain/stiffness in the morning Abnormal radiographic findings Pain at rest, relieved by activity Pain at night: Worsened by massage, analgesics ineffective Bony tenderness Poor growth Weight loss Abnormal blood results: Including complete blood count (CBC), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) |
Reasons to refer a pediatric chronic pain patient to physical therapy.
Goals of returning to sport or activities Not participating in gym class Signs of weakness, poor balance, poor endurance, abnormal movement patterns, or poor posture, etc. Diagnoses associated with abnormal movement patterns or weakness: e.g., Ehlers–Danlos syndrome, complex regional pain syndrome (CRPS), centrally mediated abdominal pain syndrome (CAPS), chronic musculoskeletal pain, chronic headaches, etc. |
Adjuvant analgesics used in pediatric pain management (Pain Medicine and Palliative Care, Children’s Hospitals and Clinics of Minnesota) [79].
| Class | Medication | Dose | Route of Administration | Comments/Side Effects (See Text for Further Details) |
|---|---|---|---|---|
|
|
| Starting dose 0.1 mg/kg QHS, usually slowly titrated up to 0.5 mg/kg (max. 20-25 mg) | PO | Tertiary amine TCA; stronger anticholinergic side effects (including sedation) than nortriptyline |
|
| Starting dose 0.1 mg/kg QHS, usually titrated up to 0.5 mg/kg (max. 20-25 mg) | PO | Secondary amine TCA; anticholinergic side effects | |
|
|
| Starting dose 2 mg/kg QHS, usually slowly titrated up to initial target dose of 6 mg/kg/dose TID (max. 300 mg/dose TID). Max. dose escalation to 24 mg/kg/dose TID (max. 1200 mg/dose TID) | PO | Slow dose increase required; side effects: ataxia, nystagmus, myalgia, hallucination, dizziness, somnolence, aggressive behaviors, hyperactivity, thought disorder, peripheral edema |
|
| Starting dose 0.3 mg/kg QHS, usually slowly titrated up to initial target dose of 1.5 mg/kg/dose BID (max. 75 mg/dose BID). Max. dose escalation to 6 mg/kg/dose BID (max. 300 mg/dose BID) | PO | Switch from gabapentin, if distressing side effects or inadequate analgesia. Side effects: ataxia, nystagmus, myalgia, hallucination, dizziness, somnolence, aggressive behaviors, hyperactivity, thought disorder, peripheral edema; Associated with weight gain | |
|
|
| Max. of 4 patches (in patients > 50 kg) 12 h on/12 h off | Transdermal patch | Not for severe hepatic dysfunction |
|
|
| 1–3 mcg/kg QHS to Q6h | PO/transdermal | |
| Infusion: 0.3 mcg/kg/h; titrate to max. 2 mcg/kg/h | IV | |||
|
|
| 0.06–0.2 mg/kg (max. 3–10 mg) QHS | PO | Sleep induction, use extended-release, if interrupted sleep, possible analgesic effect |
QHS: every night at bedtime; PO: per os, oral administration; IV: intravenous administration; BID: bis in die, twice a day; TID: ter in die, three times a day; Q6h: every 6h.
Presenting or accompanying pain conditions: Initial intake at interdisciplinary pediatric pain clinic at Children’s Minnesota.
74% Chronic or recurrent musculoskeletal pain 61% Primary headaches (tension-type/migraines) 38% CAPS 11% CRPS type I 26% Additional or accompanying underlying conditions, including
Avascular necrosis Caffe’s disease Cerebral palsy/spasticity Chiari-I-malformation with ventricular-peritoneal (VP) shunt Chronic postsurgical pain Conversion disorder CRPS type 2 Erythromelalgi Inflammatory bowel disease (Crohn’s disease, ulcerative colitis) Irritable bowel syndrome Juvenile rheumatoid/idiopathic arthritis (JRA/JIA) Malignancy Muscular dystrophy Penilodynia Phantom limb pain Progressive neurodegenerative/metabolic conditions incl. mitochondriopathies Sickle cell disease Vulvodynia |